Editor’s note: A recording of the event is embedded below
Biomarkers, including genetic alterations in tumor cells and even pieces of DNA that can be detected in the blood, are changing the way that doctors treat cancer. STAT takes a look at some of the latest technological advances.
The decisions around editorial speakers, programming and subsequent conversation(s) are driven by STAT’s editorial staff. The sponsor has no input or control over editorial conversation that occurs during the event and the speakers have received no financial compensation.
- Anna D. Barker, Ph.D., chief strategy officer, Ellison Institute for Transformative Medicine of USC; distinguished visiting fellow, complex systems, Arizona State University
- George Demetri, director, Sarcoma Center at Dana-Farber; director, Ludwig Center at Dana-Farber/Harvard Cancer Center; and executive director for Clinical and Translational Research, Ludwig Institute for Cancer Research
- Suzanne Topalian, professor of surgery and oncology, Johns Hopkins University School of Medicine; associate director, Bloomberg-Kimmel Institute for Cancer Immunotherapy
- Matthew Herper, senior writer, medicine; editorial director of events, STAT (moderator)
- Josina Reddy, M.D., Ph.D., vice president of product development for lung, agnostic, skin, rare cancers, Genentech (sponsor speaker)
Create a display name to comment
This name will appear with your comment